Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:OBIO NASDAQ:PDEX NASDAQ:POCI NASDAQ:RXST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOBIOOrchestra BioMed$3.90-2.3%$4.12$2.20▼$5.42$233.54M0.5247,281 shs138,772 shsPDEXPro-Dex$65.21-2.7%$56.16$23.47▼$68.99$208.20M-0.0238,038 shs67,026 shsPOCIPrecision Optics$5.80+4.9%$4.62$3.55▼$6.04$63.48M0.3279,320 shs67,205 shsRXSTRxSight$5.00-2.0%$6.37$4.70▼$16.00$206.99M1.14757,801 shs816,447 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOBIOOrchestra BioMed-2.26%-0.26%-5.11%-9.72%+19.63%PDEXPro-Dex-2.67%+0.68%+11.47%+43.98%+58.08%POCIPrecision Optics+4.88%+6.62%+23.14%+33.33%+23.67%RXSTRxSight-1.96%-6.19%-26.25%-34.98%-67.23%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOBIOOrchestra BioMed$3.90-2.3%$4.12$2.20▼$5.42$233.54M0.5247,281 shs138,772 shsPDEXPro-Dex$65.21-2.7%$56.16$23.47▼$68.99$208.20M-0.0238,038 shs67,026 shsPOCIPrecision Optics$5.80+4.9%$4.62$3.55▼$6.04$63.48M0.3279,320 shs67,205 shsRXSTRxSight$5.00-2.0%$6.37$4.70▼$16.00$206.99M1.14757,801 shs816,447 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOBIOOrchestra BioMed-2.26%-0.26%-5.11%-9.72%+19.63%PDEXPro-Dex-2.67%+0.68%+11.47%+43.98%+58.08%POCIPrecision Optics+4.88%+6.62%+23.14%+33.33%+23.67%RXSTRxSight-1.96%-6.19%-26.25%-34.98%-67.23%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOBIOOrchestra BioMed 2.57Moderate Buy$13.60248.72% UpsidePDEXPro-Dex 2.33Hold$70.007.35% UpsidePOCIPrecision Optics 1.00SellN/AN/ARXSTRxSight 1.93Reduce$9.4488.89% UpsideCurrent Analyst Ratings BreakdownLatest POCI, OBIO, RXST, and PDEX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026RXSTRxSight Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/19/2026OBIOOrchestra BioMed B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $10.005/19/2026PDEXPro-Dex Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/14/2026OBIOOrchestra BioMed HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.005/13/2026OBIOOrchestra BioMed BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$12.00 ➝ $13.005/12/2026PDEXPro-Dex Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $70.005/7/2026RXSTRxSight Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/7/2026RXSTRxSight Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$11.00 ➝ $9.005/7/2026RXSTRxSight Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$13.00 ➝ $11.005/1/2026PDEXPro-Dex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)4/21/2026OBIOOrchestra BioMed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOBIOOrchestra BioMed$33.48M6.98N/AN/A$0.95 per share4.11PDEXPro-Dex$66.59M3.12$3.14 per share20.80$11.23 per share5.81POCIPrecision Optics$19.09M3.32N/AN/A$1.60 per share3.63RXSTRxSight$134.48M1.54N/AN/A$6.70 per share0.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOBIOOrchestra BioMed-$52.70M-$0.97N/AN/AN/A-166.96%-157.46%-60.18%8/11/2026 (Estimated)PDEXPro-Dex$8.98M$3.6218.0123.46N/A16.08%22.78%14.30%7/8/2026 (Estimated)POCIPrecision Optics-$5.78M-$0.63N/AN/AN/A-17.03%-37.47%-19.96%N/ARXSTRxSight-$38.94M-$1.13N/AN/AN/A-36.58%-17.01%-15.12%8/6/2026 (Estimated)Latest POCI, OBIO, RXST, and PDEX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q3 2026POCIPrecision OpticsN/A-$0.01N/A-$0.01N/A$8.71 million5/12/2026Q1 2026OBIOOrchestra BioMed-$0.40-$0.33+$0.07-$0.33$0.92 million$0.11 million4/30/2026Q3 2026PDEXPro-Dex$0.62$1.20+$0.58$1.20$17.90 million$19.95 million3/12/2026Q4 2025OBIOOrchestra BioMed-$0.38$0.26+$0.64$0.26$0.93 million$30.92 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthOBIOOrchestra BioMedN/AN/AN/AN/AN/APDEXPro-DexN/AN/AN/AN/AN/APOCIPrecision OpticsN/AN/AN/AN/AN/ARXSTRxSightN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOBIOOrchestra BioMed0.357.037.01PDEXPro-Dex0.323.672.14POCIPrecision Optics0.042.101.74RXSTRxSightN/A10.208.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOBIOOrchestra BioMed53.20%PDEXPro-Dex15.28%POCIPrecision Optics13.71%RXSTRxSight78.78%Insider OwnershipCompanyInsider OwnershipOBIOOrchestra BioMed7.50%PDEXPro-Dex45.90%POCIPrecision Optics14.40%RXSTRxSight10.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOBIOOrchestra BioMed459.88 million55.39 millionNot OptionablePDEXPro-Dex1403.19 million1.73 millionNot OptionablePOCIPrecision Optics8010.94 million9.37 millionNot OptionableRXSTRxSight22041.40 million37.24 millionOptionablePOCI, OBIO, RXST, and PDEX HeadlinesRecent News About These CompaniesRxSight, Inc. (NASDAQ:RXST) Receives Average Recommendation of "Reduce" from AnalystsMay 31, 2026 | americanbankingnews.comRxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology ForumMay 19, 2026 | globenewswire.comRxSight, Inc. (RXST) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comRxSight (RXST) Q1 2026 Earnings TranscriptMay 12, 2026 | finance.yahoo.comRxSight, Inc. (RXST) Q1 2026 Earnings Call TranscriptMay 9, 2026 | seekingalpha.comRxSight (NASDAQ:RXST) Given New $9.00 Price Target at Wells Fargo & CompanyMay 7, 2026 | marketbeat.comNeedham & Company LLC Cuts RxSight (NASDAQ:RXST) Price Target to $11.00May 7, 2026 | marketbeat.comRxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2026 | zacks.comRxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales OutlookMay 6, 2026 | globenewswire.comHow The RxSight (RXST) Narrative Is Shifting After 2026 Guidance And Target ResetsMay 4, 2026 | finance.yahoo.comRxSight, Inc. to Present at the Bank of America Healthcare ConferenceApril 29, 2026 | globenewswire.comRxSight, Inc. to Report First Quarter 2026 Financial Results on May 6April 22, 2026 | globenewswire.comHow The RxSight (RXST) Story Is Shifting With New Guidance And Street Price TargetsApril 19, 2026 | finance.yahoo.comRxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026April 8, 2026 | globenewswire.comHow The Story Is Shifting For RxSight (RXST) On Guidance Leadership And ValuationApril 5, 2026 | finance.yahoo.comRxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare ConferenceApril 2, 2026 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Silence Therapeutics (SLN), RxSight (RXST) and Compass Therapeutics (CMPX)March 12, 2026 | theglobeandmail.comHow The RxSight (RXST) Investment Story Is Shifting With New Guidance And CFO ChangeMarch 7, 2026 | finance.yahoo.comRXSight, Inc. Reports Fourth Quarter and 2025 Results; Issues 2026 GuidanceFebruary 26, 2026 | markets.businessinsider.comRxSight (RXST) Q4 2025 Earnings Call TranscriptFebruary 26, 2026 | finance.yahoo.comRxSight, Inc. (RXST) Q4 2025 Earnings Call TranscriptFebruary 25, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePOCI, OBIO, RXST, and PDEX Company DescriptionsOrchestra BioMed NASDAQ:OBIO$3.90 -0.09 (-2.26%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$3.89 -0.01 (-0.26%) As of 06/5/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.Pro-Dex NASDAQ:PDEX$65.21 -1.79 (-2.67%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$65.70 +0.49 (+0.75%) As of 06/5/2026 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.Precision Optics NASDAQ:POCI$5.80 +0.27 (+4.88%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$5.92 +0.12 (+2.09%) As of 06/5/2026 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Precision Optics Corporation, Inc. designs, develops, manufactures, and sells specialized optical and illumination systems and related components primarily in the United States and the European Economic Area. It offers medical instrumentation products, including endoscopes and endocouplers, as well as other custom imaging and illumination products, such as Microprecision lenses and micro medical cameras, and 3D endoscopes for use in minimally invasive surgical procedures by hospitals and physicians. The company also provides components and assemblies for industrial and military use. It markets its products to medical device companies. The company was incorporated in 1982 and is based in Gardner, Massachusetts.RxSight NASDAQ:RXST$5.00 -0.10 (-1.96%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$4.98 -0.02 (-0.40%) As of 06/5/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
